Clendenon JN, Aranda-Michel J, Krishna M, Taner CB, Willingham DL

Language: English
References: 12
Page: 562-564
PDF size: 547.35 Kb.

ABSTRACT

Immunoglobulin G4 associated cholangitis (IAC) is an autoimmune disease associated with autoimmune pancreatitis (AIP). It presents with clinical and radiographic findings similar to primary sclerosing cholangitis (PSC). IAC commonly has a faster, more progressive onset of symptoms and it is more common to see obstructive jaundice in IAC patients compared to those with PSC. One of the hallmarks of IAC is its responsiveness to steroid therapy. Current recommendations for treatment of AIP demonstrate excellent remission of the disease and associated symptoms with initiation of steroid therapy followed by steroid tapering. If untreated, it can progress to irreversible liver failure. This report describes a 59 year-old female with undiagnosed IAC who previously had undergone a pancreaticoduodenectomy for a suspected pancreatic cancer and later developed liver failure from presumed PSC. The patient underwent an uncomplicated liver transplantation at our institution, but experienced allograft failure within five years due to progressive and irreversible bile duct injury. Radiology and histology suggested recurrence of PSC, but the diagnosis of IAC was suspected based on her past history and confirmed when IgG4 positive cells were found within the intrahepatic bile duct walls on a liver biopsy. A successful liver retransplantation was performed and the patient is currently on triple immunosuppressive therapy. Our experience in this case and review of the current literature regarding IAC management suggest that patients with suspected or recurrent PSC with atypical features including history of pancreatitis should undergo testing for IAC as this entity is highly responsive to steroid therapy.

REFERENCES

1. Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40(7): 1561-8.

2. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344(10): 732-8.

3. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, Okamoto A, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38(10): 982-4.

4. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006; 41(7): 982-4.

5. Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008; 14(25): 3948-55.

6. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, et al. Elevated Serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 4: 1010-6.

7. Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45(5): 471-7.

8. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, Okumura F, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58(11): 1504-7.

9. Björnsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007; 45(6): 1547-54.

10. Toosi MN, Heathcote J. Pancreatic pseudotumor with sclerosing pancreato-cholangitis: is this a systemic disease? Am J Gastroenterol 2004; 99: 377-82.

11. Kamisawa T, et al. Sclerosing cholangitis associated with autoimmune pancreatitis differs from primary sclerosing cholangitis. World J Gastroenterol 2009; 15(19): 2357-60.

12. Prasad P, Salem RR, Mangla R, Aslanian H, Jain D, Lee J. Lymphoplasmacytic sclerosing pancreato-cholangitis: a case report and review of the literature. Yale J Biol Med 2004; 77: 143-8.